Annovera Drug Interactions
Currently displaying 61 drugs known to have a major interaction with Annovera (ethinyl estradiol / segesterone).
- 61 major drug interactions
- 358 moderate drug interactions
- 46 minor drug interactions
Major interactions with Annovera (ethinyl estradiol / segesterone)
Note: Showing generic names only.
A
B
C
D
E
F
G
H
L
M
O
P
R
S
T
- telaprevir
- telithromycin
- testolactone
- thalidomide
- tizanidine
- tofacitinib
- topiramate
- tovorafenib
- tranexamic acid
- troleandomycin
U
Annovera alcohol/food interactions
There are 5 alcohol/food interactions with Annovera (ethinyl estradiol / segesterone).
Annovera disease interactions
There are 18 disease interactions with Annovera (ethinyl estradiol / segesterone) which include:
- smoking
- abnormal vaginal bleeding
- carcinomas (estrogenic)
- hypercalcemia in breast cancer
- hypertension
- thromboembolism/cardiovascular
- hepatic neoplasms
- angioedema
- gallbladder disease
- hypercalcemia
- hyperlipidemia
- liver disease
- melasma
- depression
- fluid retention
- glucose intolerance
- retinal thrombosis
- thyroid function tests
More about Annovera (ethinyl estradiol / segesterone)
- Annovera consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (96)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: contraceptives
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.